| Host |
Mouse |
| Clone |
MY32 |
| Format |
Concentrate |
| Method |
F, P |
| Positive control |
Skeletal Muscle |
| Dilution |
1:25 - 1:50 |
| Isotype |
Mouse IgG1 |
| Localization |
Cytoplasm |
Myosin (Skeletal Muscle)
|
Diagnostic Biosystems |
MY32 |
0.1 ml |
Concentrate |
CE/IVD |
MOB207-01 |
-
|
| Host |
Mouse |
| Clone |
MY32 |
| Format |
Concentrate |
| Method |
F, P |
| Positive control |
Skeletal Muscle |
| Dilution |
1:25 - 1:50 |
| Isotype |
Mouse IgG1 |
| Localization |
Cytoplasm |
Myosin (Skeletal Muscle)
|
Diagnostic Biosystems |
MY32 |
0.5 ml |
Concentrate |
CE/IVD |
MOB207-05 |
-
|
| Host |
Mouse |
| Clone |
MY32 |
| Format |
Ready-to-use |
| Method |
F, P |
| Positive control |
Skeletal Muscle |
| Dilution |
- |
| Isotype |
Mouse IgG1 |
| Localization |
Cytoplasm |
Myosin (Skeletal Muscle)
|
Diagnostic Biosystems |
MY32 |
6 ml |
Ready-to-use |
CE/IVD |
PDM085 |
-
|
| Host |
Mouse |
| Clone |
SMMS-1 |
| Format |
Concentrate |
| Method |
F, P |
| Pretreatment |
Citrate |
| Positive control |
Colon, appendix |
| Dilution |
1:100 - 1:500 |
| Isotype |
Mouse IgG1 |
| Immunogen |
Human uterus smooth muscle extract |
| Localization |
Cytoplasm |
Myosin SM
|
Diagnostic Biosystems |
SMMS-1 |
1 ml |
Concentrate |
CE/IVD |
MOB467 |
-
|
| Host |
Mouse |
| Clone |
SMMS-1 |
| Format |
Concentrate |
| Method |
F, P |
| Pretreatment |
Citrate |
| Positive control |
Colon, appendix |
| Dilution |
1:100 - 1:500 |
| Isotype |
Mouse IgG1 |
| Immunogen |
Human uterus smooth muscle extract |
| Localization |
Cytoplasm |
Myosin SM
|
Diagnostic Biosystems |
SMMS-1 |
0.1 ml |
Concentrate |
CE/IVD |
MOB467-01 |
-
|
| Host |
Mouse |
| Clone |
SMMS-1 |
| Format |
Concentrate |
| Method |
F, P |
| Pretreatment |
Citrate |
| Positive control |
Colon, appendix |
| Dilution |
1:100 - 1:500 |
| Isotype |
Mouse IgG1 |
| Immunogen |
Human uterus smooth muscle extract |
| Localization |
Cytoplasm |
Myosin SM
|
Diagnostic Biosystems |
SMMS-1 |
0.5 ml |
Concentrate |
CE/IVD |
MOB467-05 |
-
|
| Host |
Mouse |
| Clone |
SMMS-1 |
| Format |
Ready-to-use |
| Method |
F, P |
| Pretreatment |
Citrate |
| Positive control |
Colon, appendix |
| Dilution |
- |
| Isotype |
Mouse IgG1 |
| Immunogen |
Human uterus smooth muscle extract |
| Localization |
Cytoplasm |
Myosin SM
|
Diagnostic Biosystems |
SMMS-1 |
6 ml |
Ready-to-use |
CE/IVD |
PDM175 |
-
|
| Host |
Mouse |
| Clone |
SMMS-1 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Positive control |
Transitional cell carcinoma. |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG1 /κ |
| Immunogen |
Crude human uterus extract |
| Localization |
Nucleus |
Myosin, SMHC
|
Zeta Corporation |
SMMS-1 |
1ml |
Concentrate |
CE/IVD |
Z2229ML |
-
|
| Host |
Mouse |
| Clone |
SMMS-1 |
| Format |
Ready-to-use |
| Reactivity |
- |
| Method |
P |
| Positive control |
Transitional cell carcinoma. |
| Dilution |
- |
| Isotype |
IgG1 /κ |
| Immunogen |
Crude human uterus extract |
| Localization |
Nucleus |
Myosin, SMHC
|
Zeta Corporation |
SMMS-1 |
7 ml |
Ready-to-use |
CE/IVD |
Z2229MP |
-
|
| Host |
Mouse |
| Clone |
SMMS-1 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Positive control |
Transitional cell carcinoma. |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG1 /κ |
| Immunogen |
Crude human uterus extract |
| Localization |
Nucleus |
Myosin, SMHC
|
Zeta Corporation |
SMMS-1 |
0.5 ml |
Concentrate |
CE/IVD |
Z2229MS |
-
|
| Host |
Mouse |
| Clone |
SMMS-1 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Positive control |
Transitional cell carcinoma. |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG1 /κ |
| Immunogen |
Crude human uterus extract |
| Localization |
Nucleus |
Myosin, SMHC
|
Zeta Corporation |
SMMS-1 |
0.1 ml |
Concentrate |
CE/IVD |
Z2229MT |
-
|
| Host |
Rabbit |
| Clone |
BC15 |
| Format |
Concentrate |
| Method |
P |
| Pretreatment |
Diva modified Citrate pH 6.2 |
| Positive control |
Lung adenocarcinoma |
| Dilution |
1:100 - 1:200 |
| Isotype |
Rabbit IgG |
| Localization |
Cytoplasmic (granular) |
Napsin A
|
Biocare Medical |
BC15 |
0.1 ml |
Concentrate |
CE/IVD |
ACI3043A |
-
|
| Host |
Rabbit |
| Clone |
BC15 |
| Format |
Concentrate |
| Method |
P |
| Pretreatment |
Diva modified Citrate pH 6.2 |
| Positive control |
Lung adenocarcinoma |
| Dilution |
1:100 - 1:200 |
| Isotype |
Rabbit IgG |
| Localization |
Cytoplasmic (granular) |
Napsin A
|
Biocare Medical |
BC15 |
1 ml |
Concentrate |
CE/IVD |
ACI3043C |
-
|
| Host |
Rabbit |
| Clone |
BC15 |
| Format |
Ready-to-use |
| Method |
P |
| Pretreatment |
Diva modified Citrate pH 6.2 |
| Positive control |
Lung adenocarcinoma |
| Dilution |
- |
| Isotype |
Rabbit IgG |
| Localization |
Cytoplasmic (granular) |
Napsin A
|
Biocare Medical |
BC15 |
6 ml |
Ready-to-use |
CE/IVD |
API3043AA |
-
|
| Host |
Mouse |
| Clone |
KCG1.1 |
| Format |
Concentrate |
| Method |
F, P |
| Pretreatment |
Citrate |
| Positive control |
Lung Adenocarcinoma |
| Dilution |
1:50 - 1:100 |
| Isotype |
Mouse IgG1 |
| Localization |
Cytoplasm |
Napsin A
|
Diagnostic Biosystems |
KCG1.1 |
1 ml |
Concentrate |
CE/IVD |
MOB463 |
-
|
| Host |
Mouse |
| Clone |
KCG1.1 |
| Format |
Concentrate |
| Method |
F, P |
| Pretreatment |
Citrate |
| Positive control |
Lung Adenocarcinoma |
| Dilution |
1:50 - 1:100 |
| Isotype |
Mouse IgG1 |
| Localization |
Cytoplasm |
Napsin A
|
Diagnostic Biosystems |
KCG1.1 |
0.1 ml |
Concentrate |
CE/IVD |
MOB463-01 |
-
|
| Host |
Mouse |
| Clone |
KCG1.1 |
| Format |
Concentrate |
| Method |
F, P |
| Pretreatment |
Citrate |
| Positive control |
Lung Adenocarcinoma |
| Dilution |
1:50 - 1:100 |
| Isotype |
Mouse IgG1 |
| Localization |
Cytoplasm |
Napsin A
|
Diagnostic Biosystems |
KCG1.1 |
0.5 ml |
Concentrate |
CE/IVD |
MOB463-05 |
-
|
| Host |
Mouse |
| Clone |
KCG1.1 |
| Format |
Ready-to-use |
| Method |
F, P |
| Pretreatment |
Citrate |
| Positive control |
Lung Adenocarcinoma |
| Dilution |
- |
| Isotype |
Mouse IgG1 |
| Localization |
Cytoplasm |
Napsin A
|
Diagnostic Biosystems |
KCG1.1 |
6 ml |
Ready-to-use |
CE/IVD |
PDM154 |
-
|
| Host |
Rabbit |
| Clone |
BC15 |
| Format |
Ready-to-use |
| Method |
P |
| Pretreatment |
Citrate |
| Positive control |
lung adenocarcinoma |
| Dilution |
- |
| Isotype |
Rabbit IgG |
| Localization |
Cytoplasm |
Napsin A
|
Zytomed Systems GmbH |
BC15 |
6 ml |
Ready-to-use |
CE/IVD |
RBG059 |
-
|
| Host |
Rabbit |
| Clone |
BC15 |
| Format |
Concentrate |
| Method |
P |
| Pretreatment |
Citrate |
| Positive control |
lung adenocarcinoma |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG |
| Localization |
Cytoplasm |
Napsin A
|
Zytomed Systems GmbH |
BC15 |
0.5 ml |
Concentrate |
CE/IVD |
RBK059-05 |
-
|
| Host |
Monospecific Mouse |
| Clone |
ZM11 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Pretreatment |
Citrate or EDTA |
| Positive control |
Lung adenocarcinoma. |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG1 /κ |
| Immunogen |
Recombinant fragment of human napsin protein |
| Localization |
Cytoplasm |
Napsin A
|
Zeta Corporation |
ZM11 |
1 ml |
Concentrate |
CE/IVD |
Z2294ML |
-
|
| Host |
Monospecific Mouse |
| Clone |
ZM11 |
| Format |
Ready-to-use |
| Reactivity |
- |
| Method |
P |
| Pretreatment |
Citrate or EDTA |
| Positive control |
Lung adenocarcinoma. |
| Dilution |
- |
| Isotype |
IgG1 /κ |
| Immunogen |
Recombinant fragment of human napsin protein |
| Localization |
Cytoplasm |
Napsin A
|
Zeta Corporation |
ZM11 |
7 ml |
Ready-to-use |
CE/IVD |
Z2294MP |
-
|
| Host |
Monospecific Mouse |
| Clone |
ZM11 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Pretreatment |
Citrate or EDTA |
| Positive control |
Lung adenocarcinoma. |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG1 /κ |
| Immunogen |
Recombinant fragment of human napsin protein |
| Localization |
Cytoplasm |
Napsin A
|
Zeta Corporation |
ZM11 |
0.5 ml |
Concentrate |
CE/IVD |
Z2294MS |
-
|
| Host |
Monospecific Mouse |
| Clone |
ZM11 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Pretreatment |
Citrate or EDTA |
| Positive control |
Lung adenocarcinoma. |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG1 /κ |
| Immunogen |
Recombinant fragment of human napsin protein |
| Localization |
Cytoplasm |
Napsin A
|
Zeta Corporation |
ZM11 |
0.1 ml |
Concentrate |
CE/IVD |
Z2294MT |
-
|
| Host |
Goat |
| Clone |
polyclonal |
| Format |
Purified |
| Method |
WB |
| Dilution |
0,2 - 2 µg/mL |
| Isotype |
Goat IgG |
| Immunogen |
Peptide sequence CSESTKRKLASAV corresponding to the C-terminus of NCF1 (NP_000256) |
NCF1 (Neutrophil Cytosolic Factor 1, p47 phox)
|
Zytomed Systems GmbH |
polyclonal |
100 µg |
Purified |
RUO |
614-0007 |
-
|
| Host |
Rabbit |
| Clone |
polyclonal |
| Format |
Purified |
| Method |
F, IF, EL, WB |
| Isotype |
Rabbit IgG |
| Immunogen |
Whole cell preparation of N.meningitidis types A, B and C |
Neisseria meningitidis
|
Zytomed Systems GmbH |
polyclonal |
1 ml |
Purified |
RUO |
614-0015 |
-
|
| Host |
Rabbit |
| Clone |
EP31 |
| Format |
Concentrate |
| Method |
P |
| Pretreatment |
Citrate |
| Positive control |
Neuronal tissues, pancreas |
| Dilution |
1:50 - 1:100 |
| Isotype |
Rabbit IgG |
| Localization |
Cytoplasmic |
Nerve Growth Factor Receptor
|
Biocare Medical |
EP31 |
0.1 ml |
Concentrate |
CE/IVD |
ACI369A |
-
|
| Host |
Rabbit |
| Clone |
SP103 |
| Format |
Concentrate |
| Method |
P, WB |
| Pretreatment |
Citrate |
| Positive control |
Kidney |
| Dilution |
1:100 |
| Isotype |
Rabbit IgG |
| Immunogen |
Synthetic peptide corresponding to C-terminus of human nestin |
| Localization |
Cytoplasm |
Nestin
|
Zytomed Systems GmbH |
SP103 |
0.1 ml |
Concentrate |
RUO |
514-4030 |
-
|
| Host |
Rabbit |
| Clone |
SP103 |
| Format |
Concentrate |
| Method |
P, WB |
| Pretreatment |
Citrate |
| Positive control |
Kidney |
| Dilution |
1:100 |
| Isotype |
Rabbit IgG |
| Immunogen |
Synthetic peptide corresponding to C-terminus of human nestin |
| Localization |
Cytoplasm |
Nestin
|
Zytomed Systems GmbH |
SP103 |
0.5 ml |
Concentrate |
RUO |
514-4032 |
-
|
| Host |
Rabbit |
| Clone |
SP103 |
| Format |
Concentrate |
| Method |
P, WB |
| Pretreatment |
Citrate |
| Positive control |
Kidney |
| Dilution |
1:100 |
| Isotype |
Rabbit IgG |
| Immunogen |
Synthetic peptide corresponding to C-terminus of human nestin |
| Localization |
Cytoplasm |
Nestin
|
Zytomed Systems GmbH |
SP103 |
1 ml |
Concentrate |
RUO |
514-4034 |
-
|
| Host |
Mouse |
| Clone |
10C2 |
| Format |
Purified |
| Method |
F, P |
| Dilution |
1:50 - 1:200 |
| Isotype |
Mouse IgG1 |
Nestin
|
Zytomed Systems GmbH |
10C2 |
100 µg |
Purified |
RUO |
614-0021 |
-
|
| Host |
Mouse |
| Clone |
A60 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Pretreatment |
Citrate or EDTA |
| Positive control |
Brain tissue. |
| Dilution |
1:50 - 1:100 |
| Isotype |
IgG1 |
| Immunogen |
Purified cell nuclei from mouse brain |
| Localization |
Nucleus |
NeuN
|
Zeta Corporation |
A60 |
1 ml |
Concentrate |
CE/IVD |
Z2178ML |
-
|
| Host |
Mouse |
| Clone |
A60 |
| Format |
Ready-to-use |
| Reactivity |
- |
| Method |
P |
| Pretreatment |
Citrate or EDTA |
| Positive control |
Brain tissue. |
| Dilution |
- |
| Isotype |
IgG1 |
| Immunogen |
Purified cell nuclei from mouse brain |
| Localization |
Nucleus |
NeuN
|
Zeta Corporation |
A60 |
7 ml |
Ready-to-use |
CE/IVD |
Z2178MP |
-
|
| Host |
Mouse |
| Clone |
A60 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Pretreatment |
Citrate or EDTA |
| Positive control |
Brain tissue. |
| Dilution |
1:50 - 1:100 |
| Isotype |
IgG1 |
| Immunogen |
Purified cell nuclei from mouse brain |
| Localization |
Nucleus |
NeuN
|
Zeta Corporation |
A60 |
0.5 ml |
Concentrate |
CE/IVD |
Z2178MS |
-
|
| Host |
Mouse |
| Clone |
A60 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Pretreatment |
Citrate or EDTA |
| Positive control |
Brain tissue. |
| Dilution |
1:50 - 1:100 |
| Isotype |
IgG1 |
| Immunogen |
Purified cell nuclei from mouse brain |
| Localization |
Nucleus |
NeuN
|
Zeta Corporation |
A60 |
0.1 ml |
Concentrate |
CE/IVD |
Z2178MT |
-
|
| Host |
Rabbit |
| Clone |
ZR386 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Positive control |
Brain tissue |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG |
| Immunogen |
Recombinant fragment (around aa1-200) of human RBFOX3 (NeuN) protein (exact sequence is proprietary) |
| Localization |
Cytoplasm |
NeuN
|
Zeta Corporation |
ZR386 |
1 ml |
Concentrate |
CE/IVD |
Z2677RL |
-
|
| Host |
Rabbit |
| Clone |
ZR386 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Positive control |
Brain tissue |
| Dilution |
- |
| Isotype |
IgG |
| Immunogen |
Recombinant fragment (around aa1-200) of human RBFOX3 (NeuN) protein (exact sequence is proprietary) |
| Localization |
Cytoplasm |
NeuN
|
Zeta Corporation |
ZR386 |
7 ml |
Concentrate |
CE/IVD |
Z2677RP |
-
|
| Host |
Rabbit |
| Clone |
ZR386 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Positive control |
Brain tissue |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG |
| Immunogen |
Recombinant fragment (around aa1-200) of human RBFOX3 (NeuN) protein (exact sequence is proprietary) |
| Localization |
Cytoplasm |
NeuN
|
Zeta Corporation |
ZR386 |
0.5 ml |
Concentrate |
CE/IVD |
Z2677RS |
-
|
| Host |
Rabbit |
| Clone |
ZR386 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Positive control |
Brain tissue |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG |
| Immunogen |
Recombinant fragment (around aa1-200) of human RBFOX3 (NeuN) protein (exact sequence is proprietary) |
| Localization |
Cytoplasm |
NeuN
|
Zeta Corporation |
ZR386 |
0.1 ml |
Concentrate |
CE/IVD |
Z2677RT |
-
|
| Host |
Mouse |
| Clone |
2F11 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Positive control |
Brain. |
| Dilution |
1:50 - 1:200 |
| Isotype |
IgG1 /κ |
| Immunogen |
Human NF-H isolated brain cells |
| Localization |
Cytoplasm |
Neurofilament
|
Zeta Corporation |
2F11 |
1ml |
Concentrate |
CE/IVD |
Z2091ML |
-
|
| Host |
Mouse |
| Clone |
2F11 |
| Format |
Ready-to-use |
| Reactivity |
- |
| Method |
P |
| Positive control |
Brain. |
| Dilution |
- |
| Isotype |
IgG1 /κ |
| Immunogen |
Human NF-H isolated brain cells |
| Localization |
Cytoplasm |
Neurofilament
|
Zeta Corporation |
2F11 |
7 ml |
Ready-to-use |
CE/IVD |
Z2091MP |
-
|
| Host |
Mouse |
| Clone |
2F11 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Positive control |
Brain. |
| Dilution |
1:50 - 1:200 |
| Isotype |
IgG1 /κ |
| Immunogen |
Human NF-H isolated brain cells |
| Localization |
Cytoplasm |
Neurofilament
|
Zeta Corporation |
2F11 |
0.5 ml |
Concentrate |
CE/IVD |
Z2091MS |
-
|
| Host |
Mouse |
| Clone |
2F11 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Positive control |
Brain. |
| Dilution |
1:50 - 1:200 |
| Isotype |
IgG1 /κ |
| Immunogen |
Human NF-H isolated brain cells |
| Localization |
Cytoplasm |
Neurofilament
|
Zeta Corporation |
2F11 |
0.1 ml |
Concentrate |
CE/IVD |
Z2091MT |
-
|
| Host |
Rabbit |
| Clone |
ZR216 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Positive control |
Brain |
| Dilution |
1:100-200 |
| Isotype |
IgG |
| Immunogen |
Recombinant full-length human NEFL protein |
| Localization |
Cytoplasmic |
Neurofilament
|
Zeta Corporation |
ZR216 |
1 ml |
Concentrate |
CE/IVD |
Z2706RL |
-
|
| Host |
Rabbit |
| Clone |
ZR216 |
| Format |
ready-to-use |
| Reactivity |
- |
| Method |
P |
| Positive control |
Brain |
| Dilution |
--- |
| Isotype |
IgG |
| Immunogen |
Recombinant full-length human NEFL protein |
| Localization |
Cytoplasmic |
Neurofilament
|
Zeta Corporation |
ZR216 |
7 ml |
ready-to-use |
CE/IVD |
Z2706RP |
-
|
| Host |
Rabbit |
| Clone |
ZR216 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Positive control |
Brain |
| Dilution |
1:100-200 |
| Isotype |
IgG |
| Immunogen |
Recombinant full-length human NEFL protein |
| Localization |
Cytoplasmic |
Neurofilament
|
Zeta Corporation |
ZR216 |
0.5 ml |
Concentrate |
CE/IVD |
Z2706RS |
-
|
| Host |
Rabbit |
| Clone |
ZR216 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Positive control |
Brain |
| Dilution |
1:100-200 |
| Isotype |
IgG |
| Immunogen |
Recombinant full-length human NEFL protein |
| Localization |
Cytoplasmic |
Neurofilament
|
Zeta Corporation |
ZR216 |
0.1 ml |
Concentrate |
CE/IVD |
Z2706RT |
-
|
| Host |
Mouse |
| Clone |
RT97 |
| Format |
Purified |
| Method |
F, P |
| Pretreatment |
- |
| Positive control |
Brain, Spinal Cord |
| Dilution |
1:50 - 1:100 |
| Isotype |
Mouse IgG1 |
| Immunogen |
Triton X-100-insoluble rat brain protein |
Neurofilament H (200 kDa)
|
Zytomed Systems GmbH |
RT97 |
100 µg |
Purified |
RUO |
614-0177 |
-
|
| Host |
Sheep |
| Clone |
polyclonal |
| Format |
Lyophilised |
| Method |
WB, EL |
| Isotype |
Sheep IgG |
| Immunogen |
Affinity purified mouse 2.5S NGF |
NGF-beta (Nerve Growth Factor beta)
|
Zytomed Systems GmbH |
polyclonal |
1 mg |
Lyophilised |
RUO |
614-0070 |
-
|
| Host |
Monospecific Mouse |
| Clone |
ZM55 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Pretreatment |
Citrate or EDTA |
| Positive control |
Breast tissue. |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG2b /κ |
| Immunogen |
Recombinant human p75 NGFR protein fragment (around aa 281-421) |
| Localization |
Cytoplasm |
NGFR
|
Zeta Corporation |
ZM55 |
1 ml |
Concentrate |
CE/IVD |
Z2365ML |
-
|